Immunomodulating agents in inflammatory bowel disease: Cyclosporine and other immunomodulating agents;Inmunomoduladores en la enfermedad inflamatoria intestinal: Ciclosporina y otros inmunomoduladores

Gastroenterologia y Hepatologia Continuada

Volumn 5, Issue 2, 2006, Pages 57-61

  González Lama, Yago ^a   Gisbert, Javier P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60549095752     PISSN: 15781550     EISSN: 15787575     Source Type: Journal    
DOI: 10.1016/S1578-1550(06)74280-2     Document Type: Short Survey

References (48)

1. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. NEngl J Med. 1994;330: 1841-5.
2. Matsuhashi N, Nakajima A, Watanabe K. Tacrolimus (FK 506), a novelimosuppressive drug for inflammatory bowel disease? J Gastroenterol. 2000;35:655-657
3. Plosker G, Foster R. Tacrolimus. A further update of its pharmacology andtherapeutic use in the management of organ transplantation.Drugs. 2000;59:333-334
4. Angeloni G, Latteri M, Manna R, Rumi C, Gasbarrini G, Navarra P.Circulating levels of cyclosporin A in inflammatory bowel disease: relationshipswith lymphocyte inhibition and the age of patients. Eur J Clin Pharmacol.2004;60: 161-164
5. Hamalainen M, Lahti A, Moilanen E. Calcineurin inhibitors, cyclosporin Aand tacrolimus inhibit expression of inducible nitric oxide synthase in colonepithelial and macrophage cell lines. Eur J Pharmacol. 2002;448: 239-244
6. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V, et al.Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn'sdisease. Am J Pathol. 2001;159: 1751-1761
7. Lamprecht A, Yamamoto H, Ubrich N, Takeuchi H, Maincent P, Kawashima Y.FK506 microparticles mitigate experimental colitis with minor renal calcineurinsuppression. Pharm Res. 2005;22: 193-199
8. Yokoyama I, Hayakawa A, Hayashi S, Kobayashi T, Negita M, Takagi H. Fasantigen expression of hepatocytes and its modification by immunosuppressants.Dig Dis Sci. 1997;42: 2471-2475
9. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus andcyclosporine differ in their capacity to overcome ongoing allograft rejection asa result of their differential abilities to inhibit interleukin-10 production.Transplantation. 2002;73: 1808-1817
10. Mohamed MA, Robertson H, Booth TA, Balupuri S, Kirby JA, Talbot D.TGF-beta expression in renal transplant biopsies: A comparative study betweencyclosporin-A and tacrolimus. Transplantation. 2000;69: 1002-1005
11. Hutchinson IV, Bagnall W, Bryce P, Pufong B, Geraghty P, Brogan I.Differences in the mode of action of cyclosporine and FK 506.Transplant Proc.1998;30: 959-960
12. Kuypers DR, Claes K, Evenepoel P, Maes BD, Vanrenterghem YC. The rate ofgastric emptying determines the timing but not the extent of oral tacrolimusabsorption: simultaneous measurement of drug exposure and gastric emptying bycarbon-14-octanoic acid breath test in stable renal allograft recipients.DrugMetab Dispos. 2004;32: 1421-1425
13. Aberra FN, Lichtenstein GR. Review article: monitoring ofimmunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21:307-319
14. Chang JC, Cohen RD. Medical management of severe ulcerative colitis.Gastroenterol Clin North Am. 2004;33: 235- 50, viii.
15. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine Afor induction of remission in severe ulcerative colitis. Cochrane Database SystRev. 2005: CD004277.
16. Garcia-Lopez S, Gisbert JP, Gomollon F. Cyclosporine A in the treatmentof severe attack of ulcerative colitis: A systematic review. GastroenterolHepatol. 2005 En prensa.
17. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L,et al. Intravenous cyclosporine versus intravenous corticosteroids as singletherapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323-9.
18. Fellermann K, Luhmann D, Stange EF. Is there still a role forcyclosporine in the treatment of inflammatory bowel disease? Con argument.Inflamm Bowel Dis. 2003;9: 198-201; discussion 202-204
19. Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, PajaresGarcia JM, Mate-Jimenez J. High-dose intravenous cyclosporine in steroidrefractory attacks of inflammatory bowel disease. Hepatogastroenterology.1999;46: 2265-2268
20. Carbonnel F, Boruchowicz A, Duclos B, Soule JC, Lerebours E, Lemann M, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term andlong-term responses. Dig Dis Sci. 1996;41: 2471-2476
21. Castro B, Crespo J, Garcia-Suarez C, Fabrega E, Casafont F, Pons-RomeroF. Triple immunosuppressive therapy in the treatment of severe ulcerativecolitis. Gastroenterol Hepatol. 2004;27: 1-5.
22. Campbell S, Ghosh S. Combination immunomodulatory therapy withcyclosporine and azathioprine in corticosteroidresistant severe ulcerativecolitis: the Edinburgh experience of outcome. Dig Liver Dis. 2003;35: 546-551
23. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, et al.Long-term outcome of treatment with intravenous cyclosporin in patients withsevere ulcerative colitis. Inflamm Bowel Dis. 2004;10: 73-78
24. Domenech E, Garcia-Planella E, Bernal I, Rosinach M, Cabre E, Fluvia L,et al. Azathioprine without oral ciclosporin in the long-term maintenance ofremission induced by intravenous ciclosporin in severe, steroid- refractoryulcerative colitis. Aliment Pharmacol Ther. 2002;16: 2061-2065
25. Ortiz V, Nos P, Aguilera V, Berenguer J, Ponce J. Cyclosporin in an oralmicroemulsion as the initial treatment of corticoid- refractory ulcerativecolitis. Gastroenterol Hepatol. 2000;23: 120-122
26. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM.Cyclosporine enemas for treatmentresistant, mildly to moderately active,left-sided ulcerative colitis. Am J Gastroenterol. 1993;88: 640-645
27. Poritz LS, Rowe WA, Swenson BR, Hollenbeak CS, Koltun WA. Intravenouscyclosporine for the treatment of severe steroid refractory ulcerative colitis:what is the cost? Dis Colon Rectum. 2005;48: 1685-1690
28. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life inpatients with severe ulcerative colitis after total colectomy versus medicaltreatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999;5: 1-10.
29. Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severeulcerative colitis does not increase the rate of perioperative complications.Dis Colon Rectum. 2001;44: 1436-1440
30. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK.Cyclosporine for induction of remission in Crohn's disease. Cochrane DatabaseSyst Rev. 2005: CD000297.
31. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistulaof Crohn's disease. Dig Dis Sci. 1994;39: 374-380
32. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al.Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenouscyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125: 1025-31.
33. Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, MillisJM, et al. Clinical course and management of inflammatory bowel disease afterliver transplantation. Transplantation. 1998;65: 393-396
34. Gonzalez-Lama Y, Gisbert JP, Mate-Jimenez J. The role of tacrolimus ininflammatory bowel disease. A systematic review. Dig Dis Sci. En prensa.
35. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A,et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506).Inflamm Bowel Dis. 2002;8: 317-324
36. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus iseffective in patients with severe and refractory inflammatory bowel disease.Aliment Pharmacol Ther. 2003;17: 1273-1281
37. De Oca J, Vilar L, Castellote J, Sanchez Santos R, Pares D, Biondo S, et al. Immunodulation with tacrolimus (FK506): results of a prospective,open-label, non-controlled trial in patients with inflammatory bowel disease.Rev Esp Enferm Dig. 2003;95: 465-470
38. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oraltacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis.Aliment Pharmacol Ther. 2003;18: 415-423
39. Matsuhashi N, Nakajima A, Watanabe K, Komeno Y, Suzuki A, Ohnishi S, et al. Tacrolimus in corticosteroid- resistant ulcerative colitis. J Gastroenterol.2000;35: 635-640
40. Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of theperineum. J Clin Gastroenterol. 2000;30: 200-202
41. Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizingCrohn's disease: A pilot study. Inflamm Bowel Dis. 2005;11: 8-15.
42. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: Arandomized, placebo-controlled trial. Gastroenterology. 2003;125: 380-388
43. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy withoral tacrolimus (FK506) and azathioprine or 6-mercaptopurine fortreatmentrefractory Crohn's disease perianal fistulae. Inflamm Bowel Dis.1999;5: 239-245
44. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) inthe treatment of complicated proximal small bowel and fistulizing Crohn'sdisease. Am J Gastroenterol. 1997;92: 876-879
45. Gonzalez Lama Y, Abreu LE, Vera MI, De la Revilla J, Fernandez-Puga N,Escartin P. Long-term oral tacrolimus in refractory to infliximab fistulizingCrohn's disease: comments from Spanish experience. Gastroenterology. 2004;126:942-3; author reply 943.
46. Fellermann K, Rudolph B, Witthoft T, Herrlinger KR, Tronnier M, Ludwig D,et al. Sweet syndrome and erythema nodosum in ulcerative colitis, refractory tosteroids: successful treatment with tacrolimus. Med Klin (Munich). 2001;96:105-108
47. Kimble RM, Tickler AK, Nicholls VS, Cleghorn G. Successful topicaltacrolimus (FK506) therapy in a child with pyoderma gangrenosum. J PediatrGastroenterol Nutr. 2002;34: 555-557
48. Hodgson T, Hegarty A, Porter S. Topical tacrolimus and Crohn's disease. JPediatr Gastroenterol Nutr. 2001;33: 633.